Stoke Therapeutics, Inc. (STOK) Misses Q3 EPS by 7c
Tweet
Share
E-mailGet Alerts STOK Hot Sheet
Join SI Premium – FREE
Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q3 EPS of ($0.65), $0.07 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $10.63 million versus the consensus estimate of $6.06 million.
For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Starts DKSH Holding AG (DKSH:SW) at Overweight
- JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
- JPMorgan Starts Nippon Life India Asset Management Ltd (NAM:IN) at Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
